Wart

Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts

Retrieved on: 
Wednesday, June 14, 2023
Wuhan Institute of Biological Products, Infection, Vial, Clinical data management, Wart, Medicines and Healthcare products Regulatory Agency, Dermatology, Clinical trial, Finger, MBA, Common, Digital technology, Patient, ESourcing Capability Model, SAN, HPV, Viral, Nielsen, FDA, Phase, Skin, Safety, Pharmaceuticals and Medical Devices Agency, EDC, Fine chemical, Vaccine, Pharmaceutical industry, Plantar wart

Vial will support Nielsen with their Phase III, randomized, double-blind, placebo-controlled clinical study of CANDIN for the treatment of Verruca vulgaris (common warts) in adolescents and adults in the U.S. and Japan.

Key Points: 
  • Vial will support Nielsen with their Phase III, randomized, double-blind, placebo-controlled clinical study of CANDIN for the treatment of Verruca vulgaris (common warts) in adolescents and adults in the U.S. and Japan.
  • Vial's Dermatology CRO will work closely with the Nielsen Biosciences team through the completion of the Phase III clinical trial.
  • "Vial is thrilled to collaborate with Nielsen on their Phase III clinical trial in the U.S. and Japan.
  • We look forward to partnering with the Vial team on CANDIN's Phase III clinical trial," said David P. Burney, Ph.D., MBA, President and COO at Nielsen BioSciences.

LiVDerm Set To Launch Its Brand-New Online MOPD Foundations of Pediatric Dermatology Certificate Course

Retrieved on: 
Wednesday, June 7, 2023
Learning, Certificate of Completion of Training, Arm, PAS, Dermatophytosis, Scabies, Impetigo, Catalog, Wart, Skin, Psoriasis, Dermatology, Student, Pediatrics, MD, Patient, Practitioner, Molluscum contagiosum, Adolescence, Knowledge, Diagnosis, Pityriasis rosea, Completion, Infantile hemangioma, Tutoring, Nursing

This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.

Key Points: 
  • This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.
  • What makes this course even more appealing to busy health care professionals is the fact that it is fully online and self-paced.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Infection, Patent, Bleeding, Wart, United, Finger, Cryotherapy, MBA, Immunotherapy, Doctor of Philosophy, CQD, Nature, Patient, HPV, Viral, FDA, III, Skin, Common, Pharmaceutical industry, Nielsen

CANDIN is an approved diagnostic skin test and currently not approved by the FDA or Japan’s PMDA for the treatment of common warts.

Key Points: 
  • CANDIN is an approved diagnostic skin test and currently not approved by the FDA or Japan’s PMDA for the treatment of common warts.
  • Enrollment in Nielsen’s phase III trial for common warts treatment is expected to begin in the second half of 2023.
  • Under the terms of the license agreement, Nielsen grants Maruho an exclusive license for the post-launch sales and promotional activities of CANDIN in Japan after it is developed by Nielsen and approved by regulatory authorities.
  • With the upfront payment and milestones, Nielsen has the potential to earn greater than $100 million from the license agreement with Maruho.

Varian Introduces Isolis Cryoprobe to Simplify Planning and Guidance During Cryoablation Procedures

Retrieved on: 
Wednesday, May 10, 2023
ENT, Liver disease, Neoplasm, PALO, Wart, Cryoablation, Breast, Prostate, Gynaecology, Lung, Pain, Siemens Healthineers, Dermatology, Skin, Patient, Freezing, Kidney, Liver, General surgery, Neurology, Elective surgery, Urology, Medical imaging, Isoli, MD, Varian

PALO ALTO, Calif., May 10, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, is introducing the Isolis™ cryoprobe, a single use, disposable device designed for use with CryoCare® systems* that seeks to improve procedural efficiency and precision for cryoablation. Cryoablation is a minimally invasive, image-guided procedure for treating disease and alleviating pain by very precisely freezing and destroying tissue targets such as tumors of the lung, liver, breast, kidney, prostate, and soft tissue.

Key Points: 
  • The new Isolis cryoprobe offers the interventional radiologist greater operational control, with features designed to enhance predictability, precision, and efficiency.
  • Isolis is also the first cryoprobe to offer optional integration with the Siemens Healthineers myNeedle Laser** guidance system, which was developed for image-guided interventional procedures.
  • The clinician can use myNeedle Laser to guide the insertion and trajectory of the cryoprobe while using imaging to monitor placement progress.
  • "The Isolis cryoprobe reflects the significant opportunity Varian has as a Siemens Healthineers company to seek to raise the standards of procedural efficiency and precision," said Francis (Frank) Facchini, MD, President, Interventional Solutions at Varian.

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
CIS, Doctor of Philosophy, Associate, Icahn School of Medicine at Mount Sinai, X4, MD, WHIM syndrome, Patient, Translational research, Cell, Research and development, R, University, University of Massachusetts, Therapy, WHIM, Host, Wart, Immunology, Hospital, Rare, Pediatric Blood & Cancer, Safety, Abstract, Conference call, Rheumatology, Mount Sinai, ID, Immune system, Duke University School of Medicine, Federation of Clinical Immunology Societies, Annual Review of Cancer Biology, Restricted, ANC, SG, Clinical trial, Harvard Medical School, State Administrative Expenses, Annual general meeting, Upcoming, Pharmaceutical industry, Medical imaging, Dentistry, Management, Myelokathexis, Pediatrics, Conference, Hypogammaglobulinemia, Infection, Medicine

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.

Key Points: 
  • “This is an exciting time at X4 as we look forward to delivering on several expected major milestones throughout the rest of 2023,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $94.4 million in cash, cash equivalents, and restricted cash as of March 31, 2023.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

The Inner Circle Acknowledges, Franklin W. Harry, DPM, as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field

Retrieved on: 
Tuesday, March 21, 2023
Ankle, Chin Na, Extremities, Diabetes, Barry University, Arthritis, Pharming, Patient, Wart, Foot, Quality of life, Medicine, Anil Relia, Mentorship, Multimedia, BFF, Washington University in St. Louis, Bentley, Inner circle, Wyckoff Heights Medical Center, Diabetic foot infection, Multiple, American Board of Commissioners for Foreign Missions, Best Foot Forward, DPM, Cooking, Restaurant, Child, Diagnosis, Health, Injury, Dentistry, Podiatry

ST. LOUIS, March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Franklin W. Harry, DPM, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field.

Key Points: 
  • ST. LOUIS, March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Franklin W. Harry, DPM, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field.
  • Dr. Harry earned a Doctor of Podiatric Medicine degree from Barry University in Miami, FL.
  • A podiatrist, also known as a podiatric physician or a foot and ankle surgeon, is a medical professional devoted to treating disorders of the foot, ankle, and lower extremities.
  • Dr. Harry is the founder of Best Foot Forward and has offices in Festus and St. Louis, MO.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Skin, New Drug Application, Dermatology, Therapy, CMC, Insurance, Cantharidin, Molluscum contagiosum, Table, Bank statement, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Part, GAAP, Patient, Pharmacokinetics, Food, Carcinoma, Collaboration, FDA, Research, Safety, WEST, PDUFA, Wart, Pharmaceutical industry, Vaccine, Cryptocurrency, Torii

WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Verrica expects to initiate Part 2 of its ongoing Phase 2 study in basal cell carcinoma in the second quarter of 2023.
  • Verrica reported a net loss of $5.9 million for the fourth quarter of 2022, compared to a $9.5 million loss for the same period in 2021.
  • Research and development expenses were $3.0 million in the fourth quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2022, compared to $5.1 million for the same period in 2021.

Europe Human Papillomavirus Vaccine Market Report 2022: Growing Number of HPV Awareness Programs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Infectious Diseases, Health, Medical Supplies, Medical Devices, Wart, Disease, Woman, Penis, Hospital, Vulva, HPV, Merck & Co., Laryngeal papillomatosis, Center for Urban and Regional Analysis, Inovio Pharmaceuticals, Incidence, Vagina, GSK plc, Merck, Infection, COVID-19, Cervical cancer, Wuhan Institute of Biological Products, Anal cancer, Cancer, Vaccine, Application, Vaccitech, Sanofi, Dose

The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

Europe Human Papillomavirus Vaccine Market Report 2022: Sector to Reach $1.59 Billion by 2028 at a 4.9% CAGR

Retrieved on: 
Friday, January 27, 2023
Penis, Merck, Wart, Center for Urban and Regional Analysis, Vagina, Incidence, Infection, Laryngeal papillomatosis, HPV, Hospital, Vulva, Anal cancer, COVID-19, Wuhan Institute of Biological Products, Cancer, GSK plc, Disease, Cervical cancer, Woman, Inovio Pharmaceuticals, Merck & Co., Vaccine, Dose, Application, Vaccitech, Sanofi

The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

Retinol (Vitamin A) Global Market Report 2022: Excellent Pharmacodynamic and Pharmacokinetic Effects Propels Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Vitamins, Supplements, Health, Skin, Wart, Sigma-Aldrich, Nyctalopia, Tazarotene, Vitamin A, Meat, DSM, Egg, Serum, Xeroderma, Public health, Dairy, Research, CDC, Adapalene, Bausch, Bausch & Lomb, Food, Acne, Gel, Corneal ulcer, Animal, Growth, Patient, British Association of Dermatologists, World Health Organization, Diet, Poultry, Immunity, Statistics, Isotretinoin, Livestock, Atopic dermatitis, Prevalence, Centers for Disease Control and Prevention, WHO, Woman, Cosmetics, Pharmaceutical industry

The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Natural retinol is obtained from sources such as sweet potatoes, carrots, apricots, oranges, eggs, meat and dairy products.
  • They are present in very small quantities in daily dietary intake which led to the demand for synthetic retinol.
  • The factors responsible for their increasing demand are excellent pharmacodynamic and pharmacokinetic properties possessed by synthetic retinol.